Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zolbetuximab with Pembrolizumab and Chemotherapy in Advanced Gastric or GEJ Cancer
NCT06901531Phase 3Recruiting
- Sponsor
- Astellas Pharma
- Start
- May 2025
- Primary completion
- Sep 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing zolbetuximab + pembrolizumab + chemotherapy with Placebo + pembrolizumab + chemotherapy (2 arms). Primary endpoint: Overall Survival up to 72 months. Started May 2025; status: recruiting.
02
Drugs
zolbetuximab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06901531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06901531.